Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alvocade
- Development stage
- Phase 4
- Lead developer
- NanoAlvand
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Alvocade is a branded formulation of the proteasome inhibitor bortezomib, supplied as a lyophilized powder in vials for reconstitution and parenteral administration in oncology settings.[10] Bortezomib reversibly inhibits the 26S proteasome, disrupting targeted protein degradation, leading to accumulation of misfolded and regulatory proteins, induction of endoplasmic reticulum stress, and apoptosis, particularly in malignant plasma cells such as those in multiple myeloma and mantle cell lymphoma.[3] Alvocade is indicated for the treatment of multiple myeloma and mantle cell lymphoma and is developed and manufactured by Nanoalvand, a pharmaceutical company based in Iran.[10]
- Brand names
- Alvocade
02
Targets
PSMB6 (Proteasome 20S subunit beta 6)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on Alvocade.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alvocade.